10-Q: Fortress Biotech Q3 2025: Net Income Soars on Strategic Exits

Fortress Biotech reported a significant turnaround to net income in Q3 2025, driven by strategic asset monetizations and increased product revenue from its dermatology portfolio.

Summary

• Fortress Biotech achieved a net income of $8.8 million for the three months ended September 30, 2025, a substantial improvement from a net loss of $26.7 million in the prior year period.
• Net income attributable to Fortress common stockholders was $5.9 million for Q3 2025, compared to a net loss of $12.9 million for Q3 2024.
• Net revenue increased by 21% to $17.6 million for Q3 2025, primarily due to the U.S. commercial launch of Emrosi, which contributed $4.9 million in net product revenue.
• Research and development (R&D) expenses decreased significantly by 98% to $0.2 million for Q3 2025, largely due to the deconsolidation of Checkpoint and reduced costs at Avenue and Mustang.
• Selling, general and administrative (SG&A) expenses decreased by 21% to $17.4 million for Q3 2025, also influenced by the deconsolidation of Checkpoint.
• Other income saw a substantial increase to $17.7 million for Q3 2025, driven by a $15.1 million fair value increase in Urica's equity interest in Crystalys and a $2.6 million reversal of a repurchase obligation liability.
• For the nine months ended September 30, 2025, net income attributable to Fortress was $10.8 million, a significant improvement from a net loss of $39.2 million in the same period last year.
• The company's cash and cash equivalents increased to $86.2 million as of September 30, 2025, from $57.3 million at December 31, 2024.
• Net cash provided by financing activities increased to $71.7 million for the nine months ended September 30, 2025, up from $44.8 million in the prior year, primarily from partner company equity offerings and warrant exercises.
• The sale of Checkpoint to Sun Pharma in May 2025 generated $28.0 million in cash proceeds for Fortress and a $27.1 million gain on deconsolidation.
• Urica's dotinurad asset, now with Crystalys Therapeutics, announced a $205 million Series A financing and the initiation of two global Phase 3 trials in October 2025.
• The FDA issued a Complete Response Letter (CRL) for CUTX-101 (Menkes disease) in October 2025, citing cGMP deficiencies at the manufacturing facility, but no efficacy or safety concerns.
• Fortress paused monthly dividend payments on its Series A Preferred Stock since July 5, 2024, resulting in $10.0 million in undeclared dividends as of September 30, 2025, and impacting its Form S-3 eligibility.
• Avenue Therapeutics was formally delisted from Nasdaq in July 2025 and now trades on the OTC Markets.
• Mustang Bio's MB-106 license with Fred Hutch is facing termination due to unpaid patent expenses and maintenance fees.

Sentiment

Score: 7

Explanation: The company demonstrated significant financial improvement, turning a substantial net loss into net income, driven by strategic asset monetizations and growing product revenue from Emrosi. Cash position improved considerably. However, the preferred stock dividend pause, Nasdaq delisting of Avenue, and the CRL for CUTX-101 introduce notable concerns and risks, tempering an otherwise strong financial quarter.

Positives

• Net income attributable to Fortress common stockholders significantly improved to $5.9 million for Q3 2025, compared to a net loss of $12.9 million in Q3 2024.
• Net revenue increased by 21% quarter-over-quarter to $17.6 million, driven by the successful U.S. commercial launch of Emrosi, contributing $4.9 million.
• R&D expenses decreased by 98% to $0.2 million in Q3 2025, reflecting strategic divestitures and cost management efforts.
• SG&A expenses decreased by 21% to $17.4 million in Q3 2025, partly due to the deconsolidation of Checkpoint.
• Other income surged to $17.7 million in Q3 2025, primarily from a $15.1 million fair value increase in Urica's Crystalys equity and a $2.6 million liability reversal.
• The sale of Checkpoint to Sun Pharma generated $28.0 million in cash proceeds and a $27.1 million gain on deconsolidation, providing significant liquidity.
• Urica's dotinurad program, now under Crystalys, secured a $205 million Series A financing and initiated global Phase 3 trials, validating the asset's potential and Urica's equity stake.
• Journey Medical Corporation joined the small-cap Russell 2000 Index and the broad-market Russell 3000 Index in June 2025, enhancing visibility and liquidity.
• Mustang Bio received Orphan Drug Designation for MB-101 for recurrent diffuse and anaplastic astrocytoma and glioblastoma, a broader indication than initially proposed.
• Cash and cash equivalents increased by $28.9 million to $86.2 million as of September 30, 2025, strengthening the company's financial position.
• Total liabilities decreased by $29.7 million to $116.2 million, improving the balance sheet structure.
• The SWK Term Loan maturity date for Journey was extended from December 27, 2027, to June 27, 2028, and the revenue-based payment threshold was lowered from $70.0 million to $60.0 million, providing more flexibility.

Negatives

• Fortress has paused monthly dividend payments on its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock since July 5, 2024, with $10.0 million in undeclared dividends as of September 30, 2025.
• The dividend pause renders Fortress ineligible to use Form S-3 for new shelf registrations and has resulted in the loss of ability to use its currently effective 2024 Shelf, potentially increasing future capital raising costs and complexity.
• Avenue Therapeutics was formally delisted from Nasdaq in July 2025 and now trades on the OTC Markets, which may reduce liquidity and investor interest.
• Mustang Bio received notice of intent to terminate its CD20 License with Fred Hutch for MB-106 due to unpaid patent expenses and maintenance fees, indicating a potential setback for this program.
• The FDA issued a Complete Response Letter (CRL) for CUTX-101 (Menkes disease), citing cGMP deficiencies at the manufacturing facility, which will delay potential approval and the issuance of a Priority Review Voucher (PRV).
• There is a risk that the Rare Pediatric Disease PRV program may expire on September 30, 2026, if the 'Give Kids a Chance Act' or similar legislation is not passed, potentially preventing Cyprium from receiving a valuable PRV for CUTX-101.
• Accutane revenue decreased due to lower sales volume driven by recent market competition, highlighting vulnerability to generic competition for non-patented products.
• The company continues to have a significant accumulated deficit of $730.1 million as of September 30, 2025, indicating a history of operating losses.
• Selling, general and administrative expenses for the nine months ended September 30, 2025, increased by 34% to $81.7 million, partly due to Checkpoint's transaction-related costs and Emrosi launch expenses.

Risks

• Many product candidates are in early development stages and may never be successfully developed or commercialized, facing time and cost-intensive regulation and clinical testing.
• Competitors may develop treatments for target indications, limiting commercial opportunity and profitability.
• A history of operating losses is expected to continue, requiring substantial additional capital that may be difficult to raise.
• Existing debt agreements (e.g., Oaktree) restrict operations and require compliance with financial covenants (minimum liquidity, Journey net sales, annual capital raise), with default events adversely affecting the business.
• The pause in preferred stock dividend payments impacts eligibility for Form S-3 registration statements, potentially increasing future capital raising costs and complexity.
• Existing revenue from Journey Medical Corporation's dermatology products (Emrosi, Qbrexza, Amzeeq, Zilxi, Targadox, Exelderm) is subject to manufacturing, sales, utilization, reimbursement, and product liability risks.
• A significant portion of Journey's sales are from products without patent protection or subject to generic competition (e.g., Accutane, Targadox, Exelderm), which could significantly impact operating income.
• Continued sales and coverage depend on reimbursement from third-party payors, which are increasingly scrutinizing medical necessity and cost-effectiveness.
• The business may be adversely affected by duties, tariffs, and other trade barriers implemented by governments.
• Collaborations or divestitures may reduce business size, scope, market share, or ability to compete.
• Failure to consummate contingent dispositions of subsidiaries/assets may impair their value, and alternative arrangements may not be found on favorable terms.
• Growth and success depend on acquiring or in-licensing products and integrating them, which carries inherent risks.
• Fortress may act as guarantor/indemnitor for subsidiaries' obligations, potentially requiring substantial payments.
• Heavy reliance on third parties for manufacturing, clinical trials, and commercial product supply reduces control and may hinder timely, cost-effective development and commercialization.
• Inability to obtain and maintain patent protection or if the scope is insufficient, competitors could develop similar products.
• Costly and time-consuming litigation for infringement of third-party intellectual property rights or to enforce patents.
• Disputes with licensors may affect the ability to develop or commercialize product candidates.
• Generic drug companies may challenge patent validity and enforceability, leading to costly litigation and potential loss of patent protection.
• If approved product candidates are not broadly accepted by the healthcare community, revenues will be limited.
• Approved products may not obtain desired labels or favorable scheduling classifications, or may be subject to post-marketing requirements leading to withdrawal.
• Product liability claims could result in substantial liability and limit commercialization.
• Operating in a heavily regulated industry, future legislation or administrative action (e.g., Give Kids a Chance Act for PRV program extension) could impact operations.
• Failure to meet Nasdaq continued listing rules could lead to delisting, decreasing market liquidity and price of securities.
• Computer system failures, cyber-attacks, or cybersecurity deficiencies could disrupt operations and lead to financial, legal, and reputational harm.
• Inability to hire or retain key officers or employees could hinder business strategy and product development.
• Employees, consultants, or third-party partners may engage in misconduct or improper activities, leading to regulatory sanctions, reputational harm, and liability.
• Claims that employees/consultants wrongfully used or disclosed trade secrets of their former employers or other clients.
• Market price of securities may be volatile and disproportionate to operating performance.
• Sales or other issuances of substantial numbers of common stock shares may adversely impact price.
• Inability to manage anticipated growth from acquisitions could strain management and systems.
• Catastrophic disasters could damage facilities or cause data loss beyond insurance limits.
• Ability to use pre-change Net Operating Losses (NOLs) and other tax attributes to offset post-change taxable income or taxes may be subject to limitation.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or penalties.
• The use of artificial intelligence in the healthcare industry and challenges with properly managing its use could adversely affect the business.
• Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner.

Future Outlook

Fortress Biotech expects to continue incurring operating losses for several years as it develops and commercializes product candidates. The company believes current cash and cash equivalents are sufficient for at least the next 12 months but will require additional funding through strategic relationships, equity/debt financings, or asset sales to support R&D, regulatory filings, and commercialization efforts. Journey's minimum net sales amount under the Oaktree agreement will increase by $7.5 million each quarter, up to $80.0 million, due to Emrosi's approval. Topline data for Triplex Phase 2 trial is anticipated in early 2026. An investigator-sponsored trial for MB-109 is potentially initiating in Q2 2026. Sentynl expects to resubmit the CUTX-101 NDA shortly after addressing cGMP deficiencies. The company will adopt new accounting standards for income tax disclosures (ASU 2023-09) on December 31, 2025, and is evaluating the impact of ASU 2024-03 and ASU 2025-05.

Management Comments

• Management believes current cash and cash equivalents are sufficient to fund the Parent Entity's operations for at least 12 months following the date of filing this Quarterly Report on 10-Q.
• The Board intends to revisit its decision regarding the monthly dividend on Series A Preferred Stock regularly and will assess the profitability and cash flow of the Company to determine whether and when the pause should be lifted.
• The sale of Checkpoint is considered consistent with the company's ongoing strategy to opportunistically monetize investments in biopharma companies and assets.
• Sentynl expects to resubmit the CUTX-101 NDA shortly after addressing the cGMP deficiencies noted in the Complete Response Letter.
• Mustang intends to negotiate the terms of an arrangement with Fred Hutch pursuant to which the CD20 License is terminated in exchange for potential consideration remunerable to Mustang.

Industry Context

The biopharmaceutical industry is characterized by rapid technological change, intense competition, and heavy regulation. Fortress Biotech operates within this dynamic environment, leveraging a strategy of acquiring and advancing assets through a network of subsidiaries and partner companies. The successful launch of Emrosi by Journey Medical Corporation and the FDA approval of UNLOXCYT (prior to Checkpoint's acquisition) demonstrate the potential for commercialization within the dermatology and oncology markets. However, the CRL for CUTX-101 highlights the ongoing regulatory challenges and manufacturing complexities inherent in drug development. The delisting of Avenue Therapeutics from Nasdaq reflects the volatility and stringent listing requirements faced by smaller biopharma companies. Strategic divestitures, like Checkpoint and Baergic, are common mechanisms for companies like Fortress to monetize assets, generate liquidity, and de-risk development, while retaining potential future royalty streams. The increasing scrutiny on drug pricing and reimbursement, as well as the evolving landscape of AI in healthcare, represent broader industry trends that could impact future operations.

Comparison to Industry Standards

• The FDA approval of UNLOXCYT (cosibelimab-ipdl) for cSCC positions it in a competitive oncology market, where other PD-L1 inhibitors exist. Its commercial success will depend on its profile against established therapies.
• Emrosi's expanded payer coverage to 65% of commercial lives in the U.S. is a strong indicator of market access, comparable to successful dermatology product launches.
• The $205 million Series A financing for dotinurad by Crystalys Therapeutics, a company in which Urica holds equity, is a substantial raise for a Phase 3 gout candidate, suggesting strong investor confidence in its potential best-in-class safety and efficacy profile, especially given its prior approval in Japan.
• The CRL for CUTX-101 due to cGMP deficiencies is a common regulatory hurdle in the biopharmaceutical industry, indicating manufacturing quality control issues rather than fundamental efficacy or safety concerns, which is generally less severe than clinical trial setbacks.
• AstraZeneca's update on CAEL-101, noting a lack of statistical significance for the primary endpoint but 'highly clinically meaningful improvement' in a prespecified subgroup, is a mixed result. While not meeting the primary endpoint is a setback, the subgroup data may still support regulatory submission, a strategy sometimes pursued in rare disease indications where patient populations are small and unmet needs are high.
• The delisting of Avenue Therapeutics from Nasdaq to OTC Markets is a negative event, often associated with smaller companies struggling to meet listing requirements, and typically results in reduced liquidity and investor visibility compared to Nasdaq-listed peers.

Corporate Governance

Legal Proceedings

• No reportable events or material developments with respect to previously disclosed proceedings for the quarter ended September 30, 2025.
• The company and its subsidiaries may be subject to both insured and uninsured litigation in the ordinary course of business, including tort claims for personal injury from clinical trials and breach of contract claims.

Related Party Transactions

• Fortress has Founders Agreements with subsidiaries and partner companies (Avenue, Cellvation, Cyprium, Helocyte, Mustang, Oncogenuity, Urica) entitling it to an annual equity fee (PIK dividend) of 2.5% of fully diluted outstanding capitalization.
• Fortress has Management Services Agreements (MSAs) with Avenue, Cellvation, Cyprium, Helocyte, Mustang, Oncogenuity, and Urica, each with an annual consulting fee of $500,000 payable to Fortress.
• Fortress has a Shared Services Agreement with TG Therapeutics, Inc. (TGTX) to share the cost of certain R&D employees, invoicing TGTX $0.1 million for Q3 2025 and $0.7 million for YTD Sep 2025.
• Fortress has a Desk Share Agreement with TGTX, requiring TGTX to pay 65% of the average annual rent for Fortress's New York office space, invoicing TGTX $0.5 million for Q3 2025 and $1.4 million for YTD Sep 2025.
• Michael S. Weiss, Executive Vice Chairman, Strategic Development of Fortress, also owns Hawkins BioVentures, LLC, which provides advisory services to Mustang as Chairman of the Board for an annual cash fee of $60,000.
• Fortress has a Shared Services Agreement with Journey Medical Corporation, where Journey reimburses Fortress for salary and benefit costs of shared employees and various payroll/SG&A costs. Fortress employees provided services to Journey totaling $9,000 for Q3 2025 and $31,000 for YTD Sep 2025.
• Fortress guarantees Cyprium's 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock, which will be automatically redeemed upon a PRV Sale for CUTX-101 or exchanged for Fortress Series A Preferred Stock or cash by March 31, 2026, if no PRV Sale occurs.

Stakeholder Impact

• **Shareholders (Common Stockholders):** Experienced a significant improvement in net income attributable to Fortress, potentially boosting investor confidence. However, dilution risk from future equity raises remains, and the preferred stock dividend pause impacts the company's ability to use Form S-3, potentially affecting future capital raising efficiency and the market price of common stock.
• **Preferred Stockholders (Series A):** Monthly dividend payments have been paused since July 5, 2024, with $10.0 million in undeclared dividends as of September 30, 2025. While dividends accrue, the lack of payment impacts their immediate return and the company's S-3 eligibility.
• **Employees:** Mustang Bio's reduction in workforce and exit from its manufacturing facility indicate job impacts. The continued development of product candidates across subsidiaries provides ongoing employment opportunities.
• **Customers (Journey Medical):** The successful launch and expanded payer coverage of Emrosi indicate improved access to a new rosacea treatment. Continued sales of other dermatology products are crucial for revenue.
• **Partners/Licensors:** Strategic divestitures (Checkpoint, Baergic) and asset transfers (Dotinurad) demonstrate Fortress's ability to create value and engage in partnerships. The CRL for CUTX-101 impacts Sentynl's regulatory timeline, and the potential termination of Mustang's CD20 License with Fred Hutch highlights partnership risks.
• **Creditors (Oaktree, SWK):** Fortress and Journey are in compliance with debt covenants. The Checkpoint sale proceeds were used to reduce Oaktree principal, and Journey's SWK loan maturity was extended, indicating responsible debt management. However, the ongoing need for capital and the dividend pause could be a concern for future credit access.

Next Steps

• Sentynl Therapeutics, Inc. expects to resubmit the New Drug Application (NDA) for CUTX-101 shortly after addressing cGMP deficiencies.
• Topline data for the Phase 2 clinical trial of Triplex for adults co-infected with HIV and CMV is anticipated in early 2026.
• An investigator-sponsored single-institution trial for MB-109 (IL13R2-targeted CAR T Cells + HSV-1 oncolytic virus) is potentially initiating in the second quarter of 2026.
• The University of Alabama at Birmingham (UAB) is planning to initiate a Phase 1b study in early 2026 for MB-108 for the treatment of patients with recurrent malignant glioma.
• AstraZeneca plans to submit the pre-specified subgroup analysis from the CARES Phase 3 trials for CAEL-101 with regulatory authorities.
• Mustang intends to negotiate the terms of an arrangement with Fred Hutch for the termination of the CD20 License for MB-106.
• Fortress's Board of Directors intends to regularly revisit its decision regarding the monthly dividend on Series A Preferred Stock.
• Fortress will regain eligibility to use its 2024 Shelf registration statement on Form S-3 upon filing its Annual Report on Form 10-K, provided all accrued and future dividends on Series A Preferred Stock are paid.
• Journey Medical Corporation may offer and sell up to 3,750,000 shares of common stock under its new Journey 2025 ATM Sales Agreement.
• Crystalys Therapeutics, Inc. will advance global Phase 3 clinical studies evaluating dotinurad for the treatment of gout, with first patients dosed in October 2025.
• Fortress will adopt ASU 2023-09 on December 31, 2025, and is evaluating the impact of ASU 2024-03 and ASU 2025-05 on its financial statements.

Key Dates

Recommendation

Fortress Biotech's Q3 2025 results show a significant financial turnaround, moving from a substantial net loss to net income, driven by strategic asset monetizations (Checkpoint, Baergic) and the successful launch of Emrosi. The improved cash position and reduced R&D expenses are positive indicators. However, several material risks and uncertainties persist: the ongoing pause of preferred stock dividends impacts the company's ability to efficiently raise capital via Form S-3, Avenue's delisting from Nasdaq signals operational challenges within a subsidiary, and the Complete Response Letter for CUTX-101 introduces regulatory delays and uncertainty regarding a valuable Priority Review Voucher. The company's high accumulated deficit and continued reliance on external financing for its extensive pipeline also warrant caution. While the strategic moves and revenue growth are encouraging, the existing headwinds suggest a 'hold' recommendation, as the stock's performance will likely be influenced by the resolution of these challenges and the successful advancement of its remaining pipeline assets.

Keywords

Biopharmaceutical, Biotech, SEC Filing, 10-Q, Financial Results, Drug Development, Clinical Trials, Product Revenue, Emrosi, UNLOXCYT, Dotinurad, CAR T-cell Therapy, Menkes Disease, Gout, Rosacea, Oncology, Rare Pediatric Disease, Priority Review Voucher, Capital Raise, Debt Financing, Equity Offering, Nasdaq Delisting, Corporate Governance, Risk Factors, Fortress Biotech, Journey Medical, Mustang Bio, Avenue Therapeutics, Cyprium Therapeutics, Urica Therapeutics, Sun Pharma, Axsome Therapeutics, AstraZeneca